{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:15:45Z","timestamp":1775805345604,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T00:00:00Z","timestamp":1760918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"National Institute of Health","award":["K01AG068365"],"award-info":[{"award-number":["K01AG068365"]}]},{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oral anticoagulants are widely used to prevent recurrence in patients with venous thromboembolism (VTE), but studies of these drugs in patients with atrial fibrillation have raised concerns that warfarin may be associated with higher risk of fractures than direct oral anticoagulants. Using the United States administrative claims data from Medicare and Optum Clinformatics (January 2016 to June 2024), we conducted a cohort study that emulated a three-arm target trial of VTE patients who initiated apixaban (N\u00a0=\u00a073\u2009668), rivaroxaban (N\u00a0=\u00a030\u2009849), or warfarin (N\u00a0=\u00a020\u2009872). The primary outcome was nonvertebral fractures. Propensity score matching weights were used to balance baseline covariates. Patients were followed while on treatment; intention-to-treat (ITT) analyses were also conducted. Weighted hazard ratios while on treatment were 1.12 (95% CI, 0.89-1.41) for apixaban vs. warfarin, 1.13 (95% CI, 0.87-1.46) for rivaroxaban vs. warfarin, and 0.99 (95% CI, 0.80-1.23) for apixaban vs rivaroxaban. Results were consistent for ITT and other sensitivity analyses and across subgroups of age, sex, osteoporosis, and chronic kidney disease. Our findings suggest that apixaban, rivaroxaban, and warfarin are comparable with regards to nonvertebral fracture risk when used for VTE secondary prevention.<\/jats:p>","DOI":"10.1093\/aje\/kwaf235","type":"journal-article","created":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T11:47:24Z","timestamp":1760788044000},"page":"1027-1036","source":"Crossref","is-referenced-by-count":0,"title":["Comparative risk of nonvertebral fractures associated with oral anticoagulants in patients with venous thromboembolism"],"prefix":"10.1093","volume":"195","author":[{"given":"Zhifei","family":"Zeng","sequence":"first","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sungho","family":"Bea","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushama K","family":"Sreedhara","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3336-5412","authenticated-orcid":false,"given":"Katsiaryna","family":"Bykov","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women\u2019s Hospital and Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,20]]},"reference":[{"issue":"4","key":"2026041002343602200_ref1","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J."},{"issue":"10063","key":"2026041002343602200_ref2","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1016\/S0140-6736(16)30514-1","article-title":"Deep vein thrombosis and pulmonary embolism","volume":"388","author":"Nisio","year":"2016","journal-title":"Lancet."},{"key":"2026041002343602200_ref3","volume-title":"Venous Thromboembolism (Blood Clots)","author":"CDC","year":"2025"},{"issue":"22","key":"2026041002343602200_ref4","doi-asserted-by":"publisher","first-page":"3257","DOI":"10.1182\/bloodadvances.2018024893","article-title":"American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy","volume":"2","author":"Witt","year":"2018","journal-title":"Blood Adv."},{"key":"2026041002343602200_ref5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejim.2020.05.032","article-title":"Effects of anti-vitamin K oral anticoagulants on bone and cardiovascular health","volume":"79","author":"Marietta","year":"2020","journal-title":"Eur J Intern Med."},{"issue":"7","key":"2026041002343602200_ref6","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019618","article-title":"Fracture risks in patients treated with different oral anticoagulants: a systematic review and meta-analysis","volume":"10","author":"Huang","year":"2021","journal-title":"J Am Heart Assoc Cardiovasc Cerebrovasc Dis."},{"issue":"8","key":"2026041002343602200_ref7","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.28033","article-title":"Clinical outcomes of direct oral anticoagulants vs warfarin for extended treatment of venous thromboembolism","volume":"6","author":"Fang","year":"2023","journal-title":"JAMA Netw Open."},{"key":"2026041002343602200_ref8","doi-asserted-by":"publisher","author":"De Caterina","DOI":"10.1093\/eurheartj\/ehaa077"},{"issue":"3","key":"2026041002343602200_ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4059","article-title":"Trends in the use of oral anticoagulants for adults with venous thromboembolism in the US, 2010-2020","volume":"6","author":"Iyer","year":"2023","journal-title":"JAMA Netw Open."},{"issue":"4","key":"2026041002343602200_ref10","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1055\/s-0034-1543999","article-title":"Oral anticoagulant drugs and the risk of osteoporosis: new anticoagulants better than old?","volume":"41","author":"Tufano","year":"2015","journal-title":"Semin Thromb Hemost."},{"key":"2026041002343602200_ref11","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.896952","article-title":"Comparative risks of fracture among direct oral anticoagulants and warfarin: a systematic review and network meta-analysis","volume":"9","author":"Tsai","year":"2022","journal-title":"Front Cardiovasc Med."},{"issue":"2","key":"2026041002343602200_ref12","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1001\/jamainternmed.2019.5679","article-title":"Association of anticoagulant therapy with risk of fracture among patients with atrial fibrillation","volume":"180","author":"Lutsey","year":"2020","journal-title":"JAMA Intern Med."},{"issue":"1","key":"2026041002343602200_ref13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M19-3671","article-title":"Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation","volume":"173","author":"Lau","year":"2020","journal-title":"Ann Intern Med."},{"key":"2026041002343602200_ref14","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1016\/j.ejim.2017.07.022","article-title":"Risk of bone fractures among users of oral anticoagulants: an administrative database cohort study","volume":"44","author":"Lucenteforte","year":"2017","journal-title":"Eur J Intern Med."},{"issue":"7","key":"2026041002343602200_ref15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1161\/CIRCULATIONAHA.113.004450","article-title":"Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis","volume":"129","author":"Schulman","year":"2014","journal-title":"Circulation."},{"issue":"3","key":"2026041002343602200_ref16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1097\/MBC.0000000000000800","article-title":"Rivaroxaban and the EINSTEIN clinical trial programme","volume":"30","author":"Cohen","year":"2019","journal-title":"Blood Coagul Fibrinolysis."},{"issue":"14","key":"2026041002343602200_ref17","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"The EINSTEIN\u2013PE Investigators","year":"2012","journal-title":"N Engl J Med."},{"issue":"26","key":"2026041002343602200_ref18","doi-asserted-by":"publisher","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"The EINSTEIN Investigators","year":"2010","journal-title":"N Engl J Med."},{"issue":"8","key":"2026041002343602200_ref19","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJMoa1113697","article-title":"Extended use of dabigatran, warfarin, or placebo in venous thromboembolism","volume":"368","author":"Schulman","year":"2013","journal-title":"N Engl J Med."},{"issue":"4","key":"2026041002343602200_ref20","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1056\/NEJMx130058","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"370","author":"The Hokusai-VTE Investigators","year":"2014","journal-title":"N Engl J Med."},{"issue":"24","key":"2026041002343602200_ref21","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med."},{"issue":"4","key":"2026041002343602200_ref22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1177\/1358863X16645853","article-title":"Magnetic resonance venography to assess thrombus resolution with edoxaban monotherapy versus parenteral anticoagulation\/warfarin for symptomatic deep vein thrombosis: a multicenter feasibility study","volume":"21","author":"Piazza","year":"2016","journal-title":"Vasc Med Lond Engl."},{"issue":"5","key":"2026041002343602200_ref23","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1160\/TH08-04-0255","article-title":"Venous thromboembolism in the elderly: a community-based perspective","volume":"100","author":"Spencer","year":"2008","journal-title":"Thromb Haemost."},{"issue":"10","key":"2026041002343602200_ref24","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1093\/gerona\/glt092","article-title":"Epidemiology of fracture risk with advancing age","volume":"68","author":"Ensrud","year":"2013","journal-title":"J Gerontol Ser A."},{"issue":"7","key":"2026041002343602200_ref25","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1001\/jamainternmed.2025.1109","article-title":"Oral anticoagulation and risk of adverse clinical outcomes in venous thromboembolism","volume":"185","author":"Bea","year":"2025","journal-title":"JAMA Intern Med."},{"issue":"8","key":"2026041002343602200_ref26","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol."},{"issue":"11","key":"2026041002343602200_ref27","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1001\/jama.2022.1920","article-title":"Association of type of oral anticoagulant dispensed with adverse clinical outcomes in patients extending anticoagulation therapy beyond 90 days after hospitalization for venous thromboembolism","volume":"327","author":"Pawar","year":"2022","journal-title":"JAMA."},{"issue":"1","key":"2026041002343602200_ref28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1002\/art.42968","article-title":"Efficacy versus effectiveness: the HORIZON-pivotal fracture trial and its emulation in claims data","volume":"77","author":"D\u2019Andrea","year":"2025","journal-title":"Arthritis Rheumatol."},{"issue":"10","key":"2026041002343602200_ref29","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1002\/jbmr.3807","article-title":"The design and validation of a new algorithm to identify incident fractures in administrative claims data","volume":"34","author":"Wright","year":"2019","journal-title":"J Bone Miner Res."},{"issue":"12","key":"2026041002343602200_ref30","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1097\/MLR.0000000000000824","article-title":"Adaptation and validation of the combined comorbidity score for ICD-10-CM","volume":"55","author":"Sun","year":"2017","journal-title":"Med Care."},{"issue":"7","key":"2026041002343602200_ref31","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1093\/gerona\/glaa150","article-title":"Updating International Classification of Diseases 9th Revision to 10th Revision of a Claims-Based Frailty Index","volume":"76","author":"Gautam","year":"2020","journal-title":"J Gerontol A Biol Sci Med Sci."},{"issue":"3","key":"2026041002343602200_ref32","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1097\/EDE.0000000000000627","article-title":"Matching weights to simultaneously compare three treatment groups: comparison to three-way matching","volume":"28","author":"Yoshida","year":"2017","journal-title":"Epidemiology (Camb Mass)."},{"issue":"2","key":"2026041002343602200_ref33","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1515\/ijb-2012-0030","article-title":"A weighting analogue to pair matching in propensity score analysis","volume":"9","author":"Li","year":"2013","journal-title":"Int J Biostat."},{"issue":"10","key":"2026041002343602200_ref34","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1002\/sim.6058","article-title":"Metrics for covariate balance in cohort studies of causal effects","volume":"33","author":"Franklin","year":"2014","journal-title":"Stat Med."},{"issue":"25","key":"2026041002343602200_ref35","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","article-title":"Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples","volume":"28","author":"Austin","year":"2009","journal-title":"Stat Med."},{"issue":"9","key":"2026041002343602200_ref36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med."},{"issue":"6","key":"2026041002343602200_ref37","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1007\/s00198-014-2662-0","article-title":"Incident long-term warfarin use and risk of osteoporotic fractures: propensity-score matched cohort of elders with new onset atrial fibrillation","volume":"25","author":"Misra","year":"2014","journal-title":"Osteoporos Int."},{"issue":"1","key":"2026041002343602200_ref38","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation."},{"issue":"2","key":"2026041002343602200_ref39","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/j.chest.2024.03.003","article-title":"Antithrombotic therapy for VTE Disease: Compendium and Review of CHEST Guidelines 2012-2021","volume":"166","author":"Stevens","year":"2024","journal-title":"Chest."}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwaf235\/64818552\/kwaf235.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/4\/1027\/64818552\/kwaf235.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/4\/1027\/64818552\/kwaf235.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T06:34:42Z","timestamp":1775802882000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/195\/4\/1027\/8293175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,20]]},"references-count":39,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,20]]},"published-print":{"date-parts":[[2026,3,17]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwaf235","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,4]]},"published":{"date-parts":[[2025,10,20]]}}}